Natixis Advisors LLC Purchases 4,839 Shares of The Clorox Company (NYSE:CLX)

Natixis Advisors LLC boosted its position in The Clorox Company (NYSE:CLX) by 8.3% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 63,476 shares of the company’s stock after acquiring an additional 4,839 shares during the period. Natixis Advisors LLC’s holdings in Clorox were worth $10,341,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in CLX. Mizuho Securities USA LLC raised its stake in shares of Clorox by 46,877.8% during the 3rd quarter. Mizuho Securities USA LLC now owns 4,500,000 shares of the company’s stock valued at $733,095,000 after purchasing an additional 4,490,421 shares during the period. Nuance Investments LLC lifted its holdings in shares of Clorox by 150.6% in the second quarter. Nuance Investments LLC now owns 1,597,674 shares of the company’s stock worth $218,035,000 after buying an additional 960,094 shares in the last quarter. Van ECK Associates Corp boosted its position in shares of Clorox by 2.2% in the third quarter. Van ECK Associates Corp now owns 1,492,717 shares of the company’s stock valued at $237,372,000 after acquiring an additional 31,510 shares during the period. Bank of New York Mellon Corp boosted its position in shares of Clorox by 14.4% in the second quarter. Bank of New York Mellon Corp now owns 961,387 shares of the company’s stock valued at $131,200,000 after acquiring an additional 120,716 shares during the period. Finally, Dimensional Fund Advisors LP grew its stake in Clorox by 11.9% during the second quarter. Dimensional Fund Advisors LP now owns 802,237 shares of the company’s stock valued at $109,483,000 after acquiring an additional 85,529 shares in the last quarter. 78.53% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Clorox

In other news, EVP Angela C. Hilt sold 1,733 shares of the company’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $165.52, for a total transaction of $286,846.16. Following the completion of the transaction, the executive vice president now directly owns 13,471 shares of the company’s stock, valued at approximately $2,229,719.92. This represents a 11.40 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.57% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. Barclays raised their price target on shares of Clorox from $137.00 to $139.00 and gave the company an “underweight” rating in a report on Friday, November 1st. Jefferies Financial Group upgraded Clorox from a “hold” rating to a “buy” rating and boosted their target price for the stock from $174.00 to $187.00 in a research report on Tuesday, October 1st. BNP Paribas raised Clorox to a “strong sell” rating in a report on Friday, September 6th. DA Davidson upped their price objective on shares of Clorox from $153.00 to $171.00 and gave the stock a “neutral” rating in a research report on Monday, November 4th. Finally, Citigroup raised their target price on shares of Clorox from $165.00 to $170.00 and gave the company a “neutral” rating in a research note on Friday, September 6th. Five analysts have rated the stock with a sell rating, ten have assigned a hold rating and one has issued a buy rating to the stock. According to MarketBeat, Clorox presently has an average rating of “Hold” and a consensus target price of $155.00.

Clorox Trading Up 0.6 %

Shares of CLX opened at $169.06 on Friday. The company has a debt-to-equity ratio of 11.08, a quick ratio of 0.62 and a current ratio of 1.00. The Clorox Company has a fifty-two week low of $127.60 and a fifty-two week high of $169.21. The firm has a 50 day moving average price of $162.72 and a 200-day moving average price of $148.22. The firm has a market cap of $20.93 billion, a price-to-earnings ratio of 58.91, a PEG ratio of 3.11 and a beta of 0.41.

Clorox (NYSE:CLX) last posted its quarterly earnings results on Wednesday, October 30th. The company reported $1.86 earnings per share for the quarter, topping the consensus estimate of $1.36 by $0.50. Clorox had a net margin of 4.78% and a return on equity of 316.08%. The business had revenue of $1.76 billion during the quarter, compared to the consensus estimate of $1.64 billion. During the same period in the previous year, the firm posted $0.49 earnings per share. The firm’s revenue for the quarter was up 27.0% on a year-over-year basis. As a group, equities research analysts forecast that The Clorox Company will post 6.85 earnings per share for the current year.

Clorox Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, February 14th. Shareholders of record on Wednesday, January 29th will be paid a $1.22 dividend. The ex-dividend date of this dividend is Wednesday, January 29th. This represents a $4.88 dividend on an annualized basis and a yield of 2.89%. Clorox’s dividend payout ratio (DPR) is currently 170.03%.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.